YOLFTbeta
Oxford Biodynamics PLC

Oxford Biodynamics PLC

OBD · LSE · Healthcare / Diagnostics & Research

0.115GBX-0.00 (-4.17%)

Price History

Full chart

Market Stats

Previous Close0.12
Open0.12
Day Range0.11 – 0.13
52-Week Range0.08 – 0.75
Volume163.45M
Market Cap14.11M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta-0.17
50-Day Avg0.1186
200-Day Avg0.1878

About

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Richard Alan Compton
  • Employees37
  • Headquarters3140 Rowan Place, Oxford, United Kingdom, OX4 2WB, UK
  • Websitehttps://www.oxfordbiodynamics.com

Leadership

  • Mr. Paul Leslie Stockdale F.C.A., M.A.CFO & Executive Director · b. 1975
  • Dr. Alexandre Akoulitchev M.A., Ma (Oxon), Ph.D.Chief Scientific Officer & Executive Director · b. 1962
  • Mr. Richard Alan ComptonCEO & Executive Director · b. 1969
  • David BlumSenior Vice President of Marketing
  • Dr. Ewan Hunter B.Sc., Ph.D., Ph.D., (KCL)Chief Data Officer
  • T. DemainCompany Secretary

Financials

Income Statement

Currency: GBP2013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue350.00K659.00K702.00K1.09M1.18M1.19M907.00K456.00K341.00K154.00K510.00K636.00K1.09M
Growth (%)-+88.29%+6.53%+55.41%+8.43%+0.25%-23.52%-49.72%-25.22%-54.84%+231.17%+24.71%+72.17%
Cost of Revenue320.00K457.00K294.00K516.00K407.00K693.00K468.00K622.00K898.00K38.00K244.00K347.00K7.24M
Gross Profit30.00K202.00K408.00K575.00K776.00K493.00K439.00K-166.00K-557.00K116.00K266.00K289.00K-6.15M
Gross Margin8.57%30.65%58.12%52.70%65.60%41.57%48.40%-36.40%-163.34%75.32%52.16%45.44%-561.55%
Operating Expense1.12M967.00K1.65M2.90M4.78M3.10M4.16M4.79M6.96M8.72M11.29M13.18M4.51M
Operating Income-1.09M-765.00K-1.24M-2.33M-4.00M-2.60M-3.72M-4.95M-7.51M-8.60M-11.03M-12.89M-10.66M
Operating Margin-311.14%-116.08%-177.07%-213.38%-338.38%-219.39%-410.47%-1085.75%-2202.93%-5585.06%-2161.96%-2027.36%-973.79%
EBITDA-939.00K-688.00K-1.28M-1.91M-3.79M-2.09M-3.00M-4.42M-6.43M-6.16M-9.84M-10.27M-9.80M
EBITDA Margin-268.29%-104.40%-181.91%-174.89%-320.29%-176.39%-330.65%-970.18%-1884.75%-3999.35%-1929.61%-1613.99%-895.07%
Net Income-1.05M-736.00K-1.00M-1.73M-3.80M-1.95M-2.80M-4.31M-6.68M-6.71M-10.83M-11.57M-11.15M
Net Income Margin-301.43%-111.68%-143.16%-158.57%-321.56%-164.67%-308.71%-945.83%-1959.53%-4357.14%-2122.75%-1818.71%-1018.54%
R&D320.00K457.00K294.00K516.00K407.00K693.00K468.00K622.00K898.00K526.00K758.00K809.00K615.00K
R&D as % of Total Revenue91.43%69.35%41.88%47.30%34.40%58.43%51.60%136.40%263.34%341.56%148.63%127.20%56.16%
Interest Expense0000117.00K0080.00K114.00K195.00K213.00K225.00K422.00K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%9.89%0.00%0.00%17.54%33.43%126.62%41.76%35.38%38.54%

Balance Sheet

Currency: GBP2013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets3.60M6.18M9.74M9.02M12.68M20.94M18.79M15.35M15.38M11.34M16.13M12.11M8.09M
Total Liabilities660.00K948.00K698.00K1.28M1.08M892.00K1.20M1.77M8.69M8.76M10.07M7.75M6.97M
Total Equity2.92M5.22M9.03M7.72M11.58M20.03M17.57M13.56M6.68M2.59M6.05M4.36M1.12M
Cash3.02M5.50M8.44M7.28M10.79M18.28M5.20M6.12M2.17M974.00K5.25M1.83M1.39M
Total Debt-------541.00K6.59M6.14M6.44M5.74M5.11M
Net Debt-3.02M-5.50M-8.44M-7.28M-10.79M-18.28M-5.20M-5.58M4.41M5.16M1.19M3.91M3.72M

Cash Flow

Currency: GBP2013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow190.00K-424.00K-1.23M-1.35M-1.53M-1.94M-2.27M-3.40M-5.92M-5.18M-8.44M-10.17M-7.71M
Investing Cash Flow-48.00K1.00K-452.00K-155.00K-320.00K-678.00K-11.19M4.58M2.83M1.25M-691.00K-1.49M756.00K
Financing Cash Flow-2.92M4.50M-81.00K5.40M10.04M236.00K-181.00K-804.00K2.56M13.42M8.25M6.52M
Capital Expenditure111.00K38.00K523.00K208.00K425.00K776.00K632.00K457.00K3.09M901.00K716.00K595.00K17.00K
Free Cash Flow79.00K-462.00K-1.75M-1.56M-1.95M-2.72M-2.90M-3.86M-9.01M-6.08M-9.01M-10.77M-7.73M
Dividends Paid---0---------
FCF to OCF41.58%108.96%142.55%115.43%127.85%139.96%127.83%113.44%152.20%117.40%106.80%105.85%100.22%
Dividend Paid to FCF---0.00%---------

Earnings

Report DateDec 15, 2016Jan 31, 2017Jun 13, 2017Jan 30, 2018May 22, 2018Dec 11, 2018May 28, 2019Dec 10, 2019Jun 16, 2020Jan 28, 2021Jun 15, 2021Jan 26, 2022Jun 28, 2022Jan 24, 2023Mar 5, 2025Jun 30, 2025Dec 16, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.00----0.000.000.00
EPS Actual-0.01-0.01-0.03-0.01-0.01-0.01-0.01-0.02-0.02-0.02-0.03-0.04-0.03-0.04-0.02-0.010.00
Surprise-----------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--Pre-market--Pre-marketPre-market---

Key Statistics & Ratios

Market Cap14.11M
Enterprise Value17.22M
Trailing P/E0.00
Forward P/E0.00
Price / Sales11.81
Price / Book4.75
EPS0.00
Book Value0.001
Revenue (TTM)1.20M
Gross Profit (TTM)558.00K
EBITDA-9.13M
Profit Margin0.00%
Operating Margin-681.37%
Return on Equity-214.95%
Return on Assets-53.32%
Shares Outstanding13.44B
Shares Float3.27B
Beta-0.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%